Cure8 research brief
Noninvasive stool markers that track endoscopic inflammation could reduce the need for frequent pediatric endoscopies, easing burden and risk for children with IBD. Strong correlation with endoscopy suggests these tests may help detect active disease or recurrence.
Pediatric patients with IBD, parents/caregivers, pediatric gastroenterologists, and researchers studying noninvasive monitoring or biomarkers in IBD.
The paper suggests FC and FL measurements could serve as noninvasive alternatives to endoscopy for monitoring intestinal inflammation in childhood-onset IBD.
The study is retrospective and based on a single-center pediatric cohort, with endoscopic correlation available for a subset of patients; details such as exact thresholds, sensitivity/specificity, and longitudinal predictive performance should be checked in the full text before changing clinical monitoring.
How clinicians/patients might use this: Clinicians caring for pediatric IBD may consider fecal calprotectin and lactoferrin as useful tools for assessing mucosal inflammation alongside clinical judgment. Families should discuss with their care team whether stool biomarker monitoring is appropriate for their child’s follow-up plan.
This is a retrospective, single-center study with endoscopy performed in a subset of patients; thresholds and diagnostic performance details are in the article abstract/full text. Findings need confirmation across larger, diverse cohorts and prospective studies before replacing endoscopy for critical clinical decisions.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Fecal calprotectin measured by a point‑of‑care CGICA assay showed high accuracy for identifying colorectal inflammation and IBD in patients with chronic diarrhea, which could help avoid some unnecessary colonoscopies...
